Should I buy Xero stock? We have believed in this share since the 2020 low!
Marc Kennis, May 24, 2024
Should I buy Xero stock?
From Xero to hero: Stuart always believed in this stock. In order to answer the question “should I buy Xero stock”, Stuart Roberts shares his thoughts on Xero’s (ASX: XRO) success and future prospects. Stuart points out that Xero stands out as an accounting solution for small businesses that outsource its accounting needs. He believes the company has proven its market leadership from New Zealand to Australasia and, ultimately, the global scale.
As Stuart observes, Xero’s growth potential remains immense, citing its share price jump from $69 in November 2022 to $135 on 24 May 2024. Xero’s recent financial results were also remarkable, he says, exceeding consensus by about 100 Kiwi million dollars.
What are the Best ASX Technology Stocks to invest in right now?
Check our ASX buy/sell tips
The Rule of 40
Stuart emphasises Xero’s (ASX: XRO) ‘Rule of 40’ strategy, wherein revenue growth and earnings total more than 40. The company’s conservative yet effective financial management strategy includes calculating free cash flow rather than EBITDA. Stuart also shines a light on Xero’s (ASX: XRO) responsive approach to customer demands despite increased fees. The company’s potential to double in the next 3 to 4 years is discussed, despite the questions it poses for analysts. Stuart contrasts Xero’s 88% gross margins to the pharmaceutical industry, which is the only product line that does better.
What’s next for Xero?
Lastly, Stuart considers the future scope of Xero, predicting growth outside Australasia particularly in the US, Canada, Europe and possibly emerging markets. The company’s adaptability in foreign markets is characterised by acquiring other businesses. The incoming influence of generative AI on Xero’s already successful business model is considered a potential booster for profitability.
So, to answer the question should I buy Xero stock, Stuart draws a comparison to Nvidia (NASDAQ: NVDA) and encourages investors to consider similar burgeoning tech companies, like Xero.
Watch the entire interview here
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…
CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know
In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…